Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting

European Heart Journal

Volumn 25, Issue 18, 2004, Pages 1635-1640

  Ndrepepa, Gjin ^a   Kastrati, Adnan ^a   Neumann, Franz Josef ^b   Schmitt, Claus ^a   Mehilli, Julinda ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

Abciximab; Mortality; Myocardial infarction; Stents

Indexed keywords

ABCIXIMAB;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY STENT; FEMALE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVASCULARIZATION;

ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; STENTS; TREATMENT OUTCOME;

EID: 4444355982     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.04.031     Document Type: Article

References (24)

1. Lefkovits J., Ivanhoe R.J., Califf R.M., et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am. J. Cardiol. 77:1996;1045-1051
2. Brener S.J., Barr L.A., Burchenal J.E.B., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 98:1998;734-741
3. Neumann F.J., Kastrati A., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J. Am. Coll. Cardiol. 35:2000;915-921
4. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med. 344:2001;1895-1903
5. Antoniucci D., Rodriguez A., Hempel A., et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J. Am. Coll. Cardiol. 42:2003;1879-1885
6. Stone G.W., Grines C.L., Cox D.A., et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med. 346:2002;957-966
7. Harrell F.E. Jr. Predicting outcomes: applied survival analysis and logistic regression. 1997;University of Virginia, Charlottesville
8. Franzosi M.G., Santoro E., De Vita C., et al. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. The GISSI Investigators. Circulation. 98:1998;2659-2665
9. Baigent C., Collins R., Appleby P., et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 316:1998;1337-1343
10. Zijlstra F., Hoorntje J.C., de Boer M.J., et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N. Engl. J. Med. 341:1999;1413-1419
11. Anderson K.M., Califf R.M., Stone G.W., et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J. Am. Coll. Cardiol. 37:2001;2059-2065
12. Topol E.J., Lincoff A.M., Kereiakes D.J., et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am. J. Med. 113:2002;1-6
13. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk angioplasty. N Engl J Med 1994;330:956-61
14. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96
15. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92
16. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999;100:799-806
17. Topol E.J., Mark D.B., Lincoff A.M., et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 354:1999;2019-2024
18. Topol E.J., Neumann F.J., Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J. Am. Coll. Cardiol. 42:2003;1886-1889
19. McCallister B.D. Jr., Christian T.F., Gersh B.J., et al. Prognosis of myocardial infarctions involving more than 40% of the left ventricle after acute reperfusion therapy. Circulation. 88:1993;1470-1475
20. Neumann F.J., Blasini R., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 98:1998;2695-2701
21. Ritchie J.L., Davis K.B., Williams D.L., et al. Global and regional left ventricular function and tomographic radionuclide perfusion: the Western Washington Intracoronary Streptokinase In Myocardial Infarction Trial. Circulation. 70:1984;867-875
22. The GUSTO investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial function. N. Engl. J. Med. 1993;329:1615-22
23. Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet. 1:1989;1367-1369
24. Van de Werf F. Thrombolysis for acute myocardial infarction. Why is there no extra benefit after hospital discharge? Circulation. 91:1995;2862-2864